Neogen (NEOG) Getting Favorable Press Coverage, Study Shows

News coverage about Neogen (NASDAQ:NEOG) has trended positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Neogen earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.5984726920169 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Neogen opened at $73.50 on Friday, reports. Neogen has a 52-week low of $46.21 and a 52-week high of $75.90. The company has a market capitalization of $3.84 billion, a P/E ratio of 85.47, a PEG ratio of 4.33 and a beta of 1.27.

Neogen (NASDAQ:NEOG) last announced its quarterly earnings data on Thursday, March 22nd. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.08. Neogen had a return on equity of 11.49% and a net margin of 14.82%. The company had revenue of $95.90 million for the quarter, compared to analysts’ expectations of $97.93 million. During the same quarter in the prior year, the firm earned $0.27 earnings per share. Neogen’s revenue was up 8.5% compared to the same quarter last year. analysts expect that Neogen will post 1.14 EPS for the current year.

Several equities research analysts have recently weighed in on NEOG shares. Zacks Investment Research downgraded Neogen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 15th. BidaskClub upgraded Neogen from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Stephens reissued a “hold” rating and issued a $65.00 price objective (up previously from $62.00) on shares of Neogen in a research note on Monday, March 26th. Finally, ValuEngine raised Neogen from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $65.25.

In other Neogen news, Director Thomas H. Reed sold 6,000 shares of the stock in a transaction on Friday, March 23rd. The stock was sold at an average price of $62.47, for a total transaction of $374,820.00. Following the sale, the director now owns 19,375 shares of the company’s stock, valued at approximately $1,210,356.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Steven J. Quinlan sold 5,000 shares of the stock in a transaction on Tuesday, March 27th. The shares were sold at an average price of $66.13, for a total value of $330,650.00. Following the sale, the chief financial officer now directly owns 15,203 shares in the company, valued at approximately $1,005,374.39. The disclosure for this sale can be found here. In the last three months, insiders sold 117,320 shares of company stock worth $8,194,973. 4.20% of the stock is owned by insiders.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.

Insider Buying and Selling by Quarter for Neogen (NASDAQ:NEOG)

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with's FREE daily email newsletter.

Leave a Reply